February 13, 2019 This article originally appeared on Cancer Therapy Advisor. Share this content: A study suggests there may be a disconnect between the prevalence of germline variants in men with prostate cancer and guideline-based testing recommendations. According to results from a cross-sectiona...

February 12, 2019 Share this content: From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study. Use of active surveillance (AS) and watchful waiting (WW) for low-risk prostate cancer (PCa) increased from 2010 to 2015 in the United States. To det...

February 08, 2019 Share this content: In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles. Patients on androgen deprivation therapy (ADT) for prostate cancer may be able to ease the adverse effects of the tr...

February 07, 2019 Share this content: Men with advanced disease report health-related quality of life similar to that of those with localized disease. Most men with advanced prostate cancer (PCa) experience similar health-related quality of life to men with localized disease and even the general pop...

February 07, 2019 Share this content: Compared with patients on maintenance dialysis, men with prostate cancer and women with breast cancer have better unadjusted 5-year survival probabilities. Incident maintenance dialysis patients have worse survival than patients with some common solid organ canc...

February 04, 2019 Share this content: Weight loss in the first year after starting androgen deprivation therapy in men who have undergone radical surgery for prostate cancer ups the risk of metastatic disease and death from prostate cance Weight loss during the first year following initiation of and...

February 04, 2019 Share this content: Study finds 18 vs 6 months of androgen suppression and radiotherapy for locally advanced prostate cancer is associated with a 30% decreased risk of death from the disease. Intermediate-term androgen suppression plus radiotherapy (RT) for locally advanced prostat...

January 31, 2019 Share this content: In a study of men with nonmetastatic high-risk prostate cancer who have rising PSA after primary therapy, investigators found no significant difference in PSA progression-free survival. Adding docetaxel to androgen-deprivation therapy (ADT) does not benefit men w...

January 31, 2019 Share this content: Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves’ disease, uveitis, and psoriasis. Androgen deprivation therapy (ADT) for prostate cancer (PCa) may reduce the risk of developing autoimmune dis...

January 29, 2019 Share this content: Men with unfavorable-risk prostate cancer who had a detectable PSA nadir and a time to PSA nadir less than 12 months had a 5-fold increased risk of dying from their disease. Men with a short time to PSA nadir (TTN) and a detectable PSA nadir following external be...